Helus psilocin-based depression drug posts positive first Phase 3; second readout due late 2027
Helus Pharma's deuterated psilocin candidate HLP003 beat placebo on a standard depression scale in the first of two pivotal studies, leaving a Q4 2027 readout to set the filing timetable.
Helus Pharma has delivered the first of the two pivotal datasets it needs for HLP003, a deuterated version of psilocin being developed as an add-on treatment for adults with major depressive disorder. The company announced the topline APPROACH results on 16 November 2026. It did not disclose pricing, revenue forecasts, partnering plans or launch timing, so the commercial implications are still open.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Company's press release (SEC filing): Helus Pharma Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.